Download PDF
Semin intervent Radiol 2018; 35(02): 83-91
DOI: 10.1055/s-0038-1642622
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice

Cécile Tromeur
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
2   Department of Internal Medicine and Chest Diseases, Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Hôpital de la Cavale Blanche, CHRU, Brest, France
3   Centre d'Investigation Clinique INSERM 1412, University of Brest, Brest, France
,
Liselotte M. van der Pol
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
4   Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands
,
Albert T.A. Mairuhu
4   Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands
,
Christophe Leroyer
2   Department of Internal Medicine and Chest Diseases, Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Hôpital de la Cavale Blanche, CHRU, Brest, France
3   Centre d'Investigation Clinique INSERM 1412, University of Brest, Brest, France
,
Francis Couturaud
2   Department of Internal Medicine and Chest Diseases, Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Hôpital de la Cavale Blanche, CHRU, Brest, France
3   Centre d'Investigation Clinique INSERM 1412, University of Brest, Brest, France
,
Menno V. Huisman
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Frederikus A. Klok
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Anticoagulant therapy is the cornerstone of therapeutic management in acute venous thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis. Direct oral anticoagulants (DOACs) have become the standard of care because of their good safety profile and ease of use in clinical practice. Indeed, phase 3 randomized trials (AMPLIFY, EINSTEIN, RECOVER, and HOKUSAI studies) showed that DOACs provided a similar efficacy and a better safety than conventional treatment with parenteral heparin with overlapping loading dose of vitamin K antagonists in acute VTE therapeutic management. The results of published data from real-world registries confirm the safety and efficacy of DOACs demonstrated in the phase 3 trials.

Keywords

venous thromboembolism - DOAC - pulmonary embolism - deep venous thrombosis - anticoagulant - interventional radiology
 

  • References

  • 1 Konstantinides SV, Torbicki A, Agnelli G. , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069 , 3069a–3069k
    CrossrefPubMedGoogle Scholar
  • 2 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 3 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedGoogle Scholar
  • 4 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 5 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 6 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 7 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Kearon C, Kakkar AK. , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 9 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 10 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 11 Raskob G, Ageno W, Cohen AT. , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016; 3 (05) e228-e236
    PubMedGoogle Scholar
  • 12 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 13 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 14 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (03) 320-328
    CrossrefPubMedGoogle Scholar
  • 15 Brekelmans MP, Ageno W, Beenen LF. , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016; 3 (09) e437-e445
    PubMedGoogle Scholar
  • 16 Weitz JI, Bauersachs R, Beyer-Westendorf J. , et al; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost 2015; 114 (03) 645-650
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Cohen AT, Hamilton M, Bird A. , et al. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 2016; 11 (08) e0160064
    CrossrefPubMedGoogle Scholar
  • 18 Couturaud F, Sanchez O, Pernod G. , et al; PADIS-PE Investigators. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA 2015; 314 (01) 31-40
    CrossrefPubMedGoogle Scholar
  • 19 van der Hulle T, Tan M, den Exter PL. , et al. Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. Haematologica 2015; 100 (02) 188-193
    CrossrefPubMedGoogle Scholar
  • 20 Prandoni P, Noventa F, Ghirarduzzi A. , et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92 (02) 199-205
    CrossrefPubMedGoogle Scholar
  • 21 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362 (9383): 523-526
    CrossrefPubMedGoogle Scholar
  • 22 Schulman S, Granqvist S, Holmström M. , et al; The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336 (06) 393-398
    CrossrefPubMedGoogle Scholar
  • 23 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139 (11) 893-900
    CrossrefPubMedGoogle Scholar
  • 24 Klok FA, Kooiman J, Huisman MV, Konstantinides S, Lankeit M. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 2015; 45 (01) 201-210
    CrossrefPubMedGoogle Scholar
  • 25 Agnelli G, Prandoni P, Becattini C. , et al; Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 26 Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334 (7595): 674
    CrossrefPubMedGoogle Scholar
  • 27 Levine MN, Hirsh J, Gent M. , et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74 (02) 606-611
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340 (8824): 873-876
    CrossrefPubMedGoogle Scholar
  • 29 Kearon C, Gent M, Hirsh J. , et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340 (12) 901-907
    CrossrefPubMedGoogle Scholar
  • 30 van der Hulle T, den Exter PL, van den Hoven P. , et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer. Chest 2016; 149 (05) 1245-1251
    CrossrefPubMedGoogle Scholar
  • 31 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 32 Lee AY, Bauersachs R, Janas MS. , et al; CATCH Investigators. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13: 284
    CrossrefPubMedGoogle Scholar
  • 33 Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011; 124 (23) 2554-2559
    CrossrefPubMedGoogle Scholar
  • 34 Kvasnicka T, Malikova I, Zenahlikova Z. , et al. Rivaroxaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 2017; 18 (07) 636-642
    PubMedGoogle Scholar
  • 35 Ageno W, Eikelboom J, Lip GY. Dabigatran in clinical practice: contemporary overview of the evidence. Int J Cardiol 2016; 220: 417-428
    CrossrefPubMedGoogle Scholar
  • 36 Beyer-Westendorf J, Gelbricht V, Förster K. , et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; 78 (04) 908-917
    CrossrefPubMedGoogle Scholar
  • 37 Barco S, Lankeit M, Binder H. , et al. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial. Thromb Haemost 2016; 116 (01) 191-197
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (45) 3145-3146
    CrossrefPubMedGoogle Scholar
  • 39 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 40 Pollack Jr CV, Reilly PA, van Ryn J. , et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
    CrossrefPubMedGoogle Scholar
  • 41 Connolly SJ, Milling Jr TJ, Eikelboom JW. , et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 42 Siegal DM, Curnutte JT, Connolly SJ. , et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
    CrossrefPubMedGoogle Scholar
  • 43 Ansell JE, Bakhru SH, Laulicht BE. , et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017; 117 (02) 238-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res 2016; 146: 113-118
    CrossrefPubMedGoogle Scholar
  • 45 Lindhoff-Last E. Direct oral anticoagulants (DOAC) - management of emergency situations. Rationale and design of the RADOA-Registry. Hamostaseologie 2017; DOI: 10.5482/HAMO-16-11-0043.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Weitz JI, Haas S, Ageno W. , et al. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost 2016; 116 (06) 1172-1179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Ageno W, Mantovani LG, Haas S. , et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016; 3 (01) e12-e21
    PubMedGoogle Scholar
  • 48 Beyer-Westendorf J, Förster K, Pannach S. , et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124 (06) 955-962
    CrossrefPubMedGoogle Scholar
  • 49 Gaertner S, Cordeanu EM, Nouri S. , et al. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6-month outcomes. Int J Cardiol 2017; 226: 103-109
    CrossrefPubMedGoogle Scholar
  • 50 Cohen AT, Gitt AK, Bauersachs R. , et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017; 117 (07) 1326-1337
    Article in Thieme ConnectPubMedGoogle Scholar